Fiat Chrysler and Peugeot owner PSA Group recently announced the terms of a $48 billion merger that would create the world's fourth-largest automaker. A primary reason for the merger is to share the cost of developing electric and autonomous vehicles.

With concern growing about the United States’ ability to remain the dominant force in the global innovation economy, the STRONGER Patents Act is intended to restore and strengthen the U.S. patent system by making it easier for patent owners to enforce their intellectual property rights.

The next big technology shakeup is on its way. With a limited rollout in 2018 leading to a much more comprehensive release in 2020, 5G is here, with increased speeds, instantaneous communication, and the ability to connect just about everything.

We recently identified the ten most difficult examiners currently reviewing applications at the USPTO. Our research prompted the question: “Which firms and companies have prosecuted the most applications in front of these difficult examiners?”

In an update to our 2016, 2017, and 2018 lists of most difficult examiners at the USPTO, we have identified the 10 patent examiners (excluding SPEs) with the most skeptical eye toward the patent applications that cross their desks.

The USPTO has announced its intention to extend the After Final Consideration Pilot (AFCP) 2.0 program through September 30, 2020. The program had been set to expire on September 30, 2019.

For patent applicants looking to move quickly, the USPTO's Track One program is a seemingly obvious choice. But does the program, which was instituted in 2011, still work? The answer is yes – but not like it used to.

We often use allowance rate as a quick and simple way to quantify success at the USPTO -- and we know law firms use it too. However, that is just one of many indicators in-house counsel can use to evaluate firm performance. 

In the world of patent applications, timing is key. When your firm receives an office action, a quick and thorough response helps ensure smooth communication with your examiner and calms your anxious client.

Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.